Table 4 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer | Synapse
October 2, 2025
Table 4 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Key Points
Combination therapy resulted in serious adverse events, impacting patient safety.
Grade 3 or 4 TESAEs occurred in more than one patient, affecting the safety profile of the treatment.
The study involved patients with advanced breast cancer who had not received prior systemic therapy.
Findings suggest the need for careful monitoring of side effects for this drug combination.
Abstract
Grade 3 or 4 TESAEs, of any cause, occurring in >1 patient, N = 41.